CN109453184A - The new opplication of Catalpol - Google Patents
The new opplication of Catalpol Download PDFInfo
- Publication number
- CN109453184A CN109453184A CN201811521163.9A CN201811521163A CN109453184A CN 109453184 A CN109453184 A CN 109453184A CN 201811521163 A CN201811521163 A CN 201811521163A CN 109453184 A CN109453184 A CN 109453184A
- Authority
- CN
- China
- Prior art keywords
- catalpol
- trichomadesis
- mouse
- hair
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 title claims abstract description 39
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 title claims abstract description 39
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 title claims abstract description 39
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 210000004209 hair Anatomy 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 6
- 238000012423 maintenance Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 241000405414 Rehmannia Species 0.000 abstract description 5
- 238000005406 washing Methods 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 210000003491 skin Anatomy 0.000 description 19
- 210000003780 hair follicle Anatomy 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 238000004043 dyeing Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010050789 Hypochromasia Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101150056774 SHG1 gene Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003718 aged appearance Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 210000001308 heart ventricle Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- -1 monosaccharide glycosides compound Chemical class 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides the new application of Catalpol, i.e. application of the Catalpol in preparation treatment trichomadesis drug, Catalpol maintains the application in hair cosmetic composition in preparation, and Catalpol is preparing the application being suitble in trichomadesis crowd edible food.Glutinous rehmannia extract Catalpol can prepare treatment trichomadesis drug, for preventing and treating trichomadesis；Maintenance hair cosmetic composition can be prepared, daily hair washing, hair care are used for；Catalpol can prepare suitable trichomadesis crowd edible food, improve function of human body, alleviate trichomadesis.
Description
Technical field
The present invention relates to the new applications of Catalpol.
Specifically, being the application for being related to Catalpol in preparation treatment trichomadesis drug, Catalpol maintains hair in preparation
Application in cosmetics, Catalpol are preparing the application being suitble in trichomadesis crowd edible food.
Background technique
The root tuber of glutinous rehmannia system scrophulariaceae rehmannia glutinosa plant, to commonly use large Chinese medicine.There are cultivation, main producing region river in all parts of the country
North, Henan, Shanxi, Shandong.
Catalpol is a kind of iridoid monosaccharide glycosides compound, molecular formula C15H22O10.It is the principle active component of glutinous rehmannia
One of, molecular weight 362 is unstable under acid-base condition.Modern pharmacological research proves that Catalpol has anticancer, Anti-alzheimer's disease, drop
The effects of blood pressure and blood lipoid, hepatitis virus resisting, laxative, antibacterial anti-inflammatory, diuresis, spasmolysis, suppression to capillary permeability.
The further investigation of glutinous rehmannia chemical component will be helpful to the exploitation of Chinese medicine glutinous rehmannia tradition effective substance illustrated with new drug
Work.
Summary of the invention
The purpose of the present invention is to provide the new applications of Catalpol.
Application of the Catalpol in preparation treatment trichomadesis drug.
Catalpol used in the present invention can be used alone or be used with pharmaceutical compositions.Pharmaceutical composition includes making
For the Catalpol and pharmaceutical carrier of active constituent.
Catalpol and pharmaceutical carrier can be derived from commercially available or be obtained using prior art preparation.
The pharmaceutical composition can by it is oral, sublingual, percutaneous, give through muscle or subcutaneous, mucocutaneous, intravenous route
Medicine.Pharmaceutical composition can exist in the form of injection, powder-injection, tablet, capsule, soft capsule, dripping pill or oral solution.
The dosage of Catalpol in the present invention, it is different because of the difference such as the state of patient, weight, administration mode.
Application of the Catalpol in preparation maintenance hair cosmetic composition.
Catalpol is preparing the application being suitble in trichomadesis crowd edible food.
Due to using above technical scheme, compared with prior art, beneficial effects of the present invention: the present invention mentions for Catalpol
New application has been supplied, its application range is expanded.It can be seen that Catalpol from appearance and skin HE coloration result and inhibit mouse aging
Trichomadesis, there is improvement result to the morphology of skin follicle, illustrate that Catalpol has the function of inhibition trichomadesis.
Present invention will be further explained below with reference to the attached drawings and specific embodiments.
Detailed description of the invention
Attached drawing 1 is that mouse weight record compares figure.
Attached drawing 2 is that mouse hair and hair follicle HE picture compare figure.
Specific embodiment
Embodiment:
1, experiment purpose: application of the research Catalpol in treatment trichomadesis.
2, experimental material.
2.1, experimental animal: strain: healthy Kunming mouse, 24；Gender: half male and half female；22 ± 2g of weight；Source:
Jinan friend pleases experimental animal and breeds Co., Ltd, credit number: the Shandong SCXK(20140007)；Rearing conditions: constant-temperature purification ventilation
Animal house, 20-25 DEG C of temperature, humidity 50%-60% divides cage to feed, natural circadian rhythm illumination, feed food and water freely.
2.2, Catalpol: Suo Laibao biotechnology company, lot number: 20161124.The structure of Catalpol is as schemed.
2.3, other reagents: alcohol: Xin Teng Pharmaceuticals Ltd, Xintai City, lot number: 170266；Chloraldurate: Tianjin light
Multiple fine chemistry industry research institute, lot number: 20160322；Frozen section embedding medium: Shanghai Rui Bosai biotechnology company；HE reagent
Box: Suo Laibao biotechnology company, lot number: 20161223；Physiological saline: Kelun Pharm Ind Co., Ltd., Sichuan；Poly first
Aldehyde: fine chemistry industry research institute, lot number: 20141012 are recovered in Tianjin；Ethyl alcohol: Laiyang economic and technological development zone Fine Chemical Works,
Lot number: 20161122；Dimethylbenzene: Tianjin Heng Xing chemical reagent Manufacturing Co., Ltd, lot number: 20160915.
2.4, laboratory apparatus: balance: Ohaus Instrument (Changzhou) Co., Ltd., model: AX224ZH；Freezing microtome (contains
Blade): come card microscopic system (Shanghai) trade Co., Ltd, model: CM3050S；Microscope: Japanese Nikon company, model: C-
SHG1；20ml syringe: He'nan Shuguang Jianshi Medical Equipment Group Co., Ltd., lot number: 20160304；2.5ml injection
Device: Nanyang Jiu Kang Medical Devices Co., Ltd., lot number: 20161225；Surgical instrument: 12.5cm haemostatic clamp (curved), 10cm solution
It cuts open and cuts (straight), 9.5cm eye scissors (straight), 9.5cm eye scissors (curved), straight forceps (tooth), curved tweezer (tooth), the limited public affairs of the new boat science and technology of China
Department.
3, experimental method.
Healthy Kunming mouse 24 is taken, aged control, administration group are randomly divided into, conventinal breeding to 16 monthly ages is established
Aged Mice model.
Wherein, aged control mouse is normally raised, and without any processing, feeds to 16 monthly ages.
Wherein, administration group mouse begins that Catalpol 5mg/kg/d is injected intraperitoneally from the 13rd monthly age, once a day, in daily morning 9
Point or so administration, it is continuous to inject 3 months to 16 monthly age of mouse.
In addition take healthy adult mouse 10 (2 monthly age) as Normal group.
3.1, weight records.
(2 monthly age) weighing before the experiment of all experiment mices (unit g) is simultaneously recorded, feed to 6 monthly ages, 12 monthly ages, 14 monthly ages,
16 monthly ages weighed record respectively, and the weighing body weight time is daily morning 8:30 or so.
3.2, hair growth situation records.
Root it is documented that, mouse began to enter declining periods from 12 monthly ages, and aged control and administration group mouse exist respectively
12 monthly ages carried out photographing to record its hair situation, then took pictures within every 2 months primary, compared 2 groups of animal hair dropping situations.
3.3, the perfusion fixation and materials of mouse.
Mouse is anaesthetized with 10% chloral hydrate anesthesia 10mg/Kg, and dorsal position is fixed, and opens chest exposure heart, and left ventricle cuts off one
Osculum, puncture needle is inserted into aorta ascendens by left ventricle: syringe needle is rapidly entered through notch through left ventricle, atrium sinistrum, aorta
Valve arrives at aorta ascendens.Cut off right auricle of heart bloodletting, quick filling physiological saline, until liver, kidney and other organs are by blood red discoloration
For pale asphyxia, right auricle of heart flows out every mouse of colourless liquid and physiological saline about 500ml is perfused.4% paraformaldehyde is replaced immediately after
Solution is irrigated.4% paraformaldehyde solution needs fresh configuration before use, places 4 DEG C of pre-coolings.The perfusion of 4% paraformaldehyde solution
There is general tremor in initial stage mouse, hind leg is swung, tail stretches, and illustrates fixer perfusion in place, at this moment continues that 4% poly is perfused
The total 500ml/ of formalin only, terminates perfusion.The hair in back of mice and mouth skin is lightly struck off with blade, is removed small
The skin of back (about 4cm2) and mouth skin of mouse put into fixed in 4% paraformaldehyde solution, 4 DEG C of refrigerators preservations immediately.
Every mouse takes the position of skin to be consistent as far as possible.
3.4, hair follicle morphological examination HE is dyed.
It is first turned on freezing microtome when slice, is down to -20 DEG C to temperature, takes out skin histology, embedded, put with embedding medium
Enter in freezing microtome and freeze, be then sliced, piece is 5 μm thick.Slice first passes through the fixed 30s of 95% ethyl alcohol, histotomy deionization
Washing 2 times, each 1min, then haematoxylin dyeing 2min, flowing water rinse 10-15s, hydrochloride alcohol color separation color 10-30s, in time
Microscopy color separation degree makes the part for not needing coloring fade completely, and the colored parts that should be coloured are appropriate.Shading criteria: karyon is
Navy blue, cytoplasm are light grey or colourless.Flowing water rinses 10-15s, and with ammonium hydroxide oil blackeite 1-3s, deionization washes 2s, can after washing
Under the microscope, if hypochromasia, it can need to return to haematoxylin and be dyed；Eosin stains are less than 1min, in time under the microscope, dyeing
Unsuitable too deep, light red, good dyeing should reach the depth that cell heterogeneity dyes and color contrast is significant.Gradient second
Dehydration of alcohols, dimethylbenzene are transparent: each in dimethylbenzene I, dimethylbenzene II respectively to place 1min in 80% ethyl alcohol, 95% ethyl alcohol, dehydrated alcohol
Place 2min.Neutral gum: being instilled the tissue of glass slide, coverslip is taken slowly to cover from one end by neutral gum mounting,
It avoids generating bubble.Microscopy observes HE coloration result.
4, result.
4.1, changes of weight.
As shown in Fig. 1, the weight of mouse is gradually increased with nursing time, until 16 monthly ages, aged control and administration
Group mouse weight is significantly higher than Normal group, and difference is statistically significant, equal p < 0.01.But administration group and old age
There is no significant difference between control group mice weight, compares p > 0.05 two-by-two respectively in different time sections weight.
4.2, mouse appearance compares.
Administration group mouse started medication from 13rd month, so 12 months and the appearance of mouse has carried out unified ratio in the past
Compared with until the appearance of 2 groups of mouse is respectively compared at the end of administration in 16 months.
Healthy adult mouse chaeta is bright, submissive, compares docile limbs.
With the gradually extension of nursing time, the hair of mouse gradually becomes dilute without pharmaceutical intervention
It dredges, the most obvious with mouth trichomadesis, until 12 months, the mouth trichomadesis of most of mouse, skin is exposed.
It feeds to the 16th monthly age, aged control mouse has shown that apparent aged appearance, the back of some animals
It falls off with mouth hair large area, skin is exposed.The appearance of administration group mouse is taken on a new look much with respect to aged control, and hair is more
Light falls off also less.
4.3, mouse hair and hair follicle HE picture compare.
As shown in Fig. 2, A1, A2, A3 are respectively 3 groups of back of mice skins in figure；B1, B2, B3 are respectively 3 groups of back of mices
The longitudinal sectional observation of skin；C1, C2, C3 are respectively 3 groups of Mice Mice mouth skins.
The skin follicle and hair marshalling of Normal group mouse (healthy adult mouse), quantity is more, and hair follicle is mellow and full,
Sharpness of border, basophilla dyeing is deeper, illustrates that stem cell is active, visible 2-3 root hair in most single hair follicles.
Most hair follicle atrophys of aged control mouse, appearance are in long shuttle-type, and segment boundary is unclear, and basophilla dyeing is shallow,
Hair significantly reduces, most of in the single hair follicle of finding that 1 hair is only presented.
Administration group mouse skin hair follicle and hair are clearly better compared with aged control, and hair follicle form is small close to Normal group
Mouse, it is in single hair follicle to be presented 2 hairs more, in some hair follicles or even visible 3 hairs.
5, conclusion.
This test is fed since 2 monthly ages of mouse, and healthy adult mouse chaeta is bright, submissive, compares docile limbs, with
The growth at monthly age, until 12 monthly ages visible most of mouse hair color brightness reduces, chaeta is loose, and mouth trichomadesis is more bright
It is aobvious；To 16 monthly ages, it is seen that aged control mouse hair is coarse, loose, and most of mouse mouth, the back of some animals are obvious
It can be seen that trichomadesis, these appearances of the mouse of administration group all obviously fall off with aged control, especially mouth skin and hair well
It reduces, back there are no apparent trichomadesis.
Mouse is put to death after 16 monthly ages takes back and mouth skin that rear slice row HE dyeing is fixed, while taking health 2 months
Rear slice row HE dyeing, compared with Normal group, the skin follicle of aged control mouse is fixed in the mouse skin in age
Atrophy, most hair follicles are interior to be only presented 1 hair；And Catalpol administration group hair follicle form is close to Normal group mouse, single hair follicle
It is interior be presented 2 hairs, in some hair follicles or even visible 3 hairs.
In summary results, it can be seen that continuously to give Catalpol within 3 months not significant for the weight of mouse for intraperitoneal injection
It influences.But can be seen that the trichomadesis that Catalpol inhibits mouse from appearance and skin HE coloration result, to skin follicle
Morphology has improvement result, these results illustrate that Catalpol has the function of inhibiting trichomadesis.
According to this as a result, relating to Catalpol belongs to compound safe to the human body, it is used for a long time without obvious toxic-side effects, ground
Yellow extract Catalpol can prepare treatment trichomadesis drug, for preventing and treating trichomadesis；Maintenance hair can be prepared
Cosmetics are used for daily hair washing, hair care；Catalpol can prepare suitable trichomadesis crowd edible food, improve function of human body, delay
Solve trichomadesis.
One embodiment of the present invention has been described in detail above, but the content is only preferable implementation of the invention
Example, should not be considered as limiting the scope of the invention.It is all according to all the changes and improvements made by the present patent application range
Deng should all fall within the scope of the patent of the present invention.
Claims (3)
1. application of the Catalpol in preparation treatment trichomadesis drug.
2. application of the Catalpol in preparation maintenance hair cosmetic composition.
3. Catalpol is preparing the application being suitble in trichomadesis crowd edible food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811521163.9A CN109453184A (en) | 2018-12-13 | 2018-12-13 | The new opplication of Catalpol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811521163.9A CN109453184A (en) | 2018-12-13 | 2018-12-13 | The new opplication of Catalpol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109453184A true CN109453184A (en) | 2019-03-12 |
Family
ID=65613168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811521163.9A Pending CN109453184A (en) | 2018-12-13 | 2018-12-13 | The new opplication of Catalpol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109453184A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055022A (en) * | 2013-01-10 | 2013-04-24 | 济南康众医药科技开发有限公司 | Method for processing rehmannia and application for rehmannia in preparation for medicine |
| CN103860571A (en) * | 2012-12-12 | 2014-06-18 | 玄振玉 | Novel application of catalpol |
-
2018
- 2018-12-13 CN CN201811521163.9A patent/CN109453184A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103860571A (en) * | 2012-12-12 | 2014-06-18 | 玄振玉 | Novel application of catalpol |
| CN103055022A (en) * | 2013-01-10 | 2013-04-24 | 济南康众医药科技开发有限公司 | Method for processing rehmannia and application for rehmannia in preparation for medicine |
Non-Patent Citations (2)
| Title |
|---|
| 王静欢等: "梓醇多效性相关信号通路研究进展", 《中国药理学通报》 * |
| 胡方: "高效液相色谱法同时测定斑秃丸中梓醇、麦角甾苷、吉奥诺苷B_1、马替诺皂苷、二苯乙烯苷、大黄素甲醚和芍药苷的含量", 《中南药学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Carlisle et al. | Endocrine control in crustaceans | |
| Yoffey | A contribution to the study of the comparative histology and physiology of the spleen, with reference chiefly to its cellular constituents: I. in fishes | |
| Tyson | The fine structure of the maxillary gland of the brine shrimp, Artemia salina: the end-sac | |
| Burtt | On the corpora allata of dipterous insects. II | |
| JP5024985B2 (en) | Fish labeling and labeling methods | |
| CN109453184A (en) | The new opplication of Catalpol | |
| Lala | Influence of local environment on the growth parameters of the Ehrlich ascites tumor | |
| Hoggan et al. | On the Development and Retrogression of the Fat‐cell | |
| CN109453294B (en) | Application of Xinmaian in promoting hair growth | |
| Carman | Variation in the maximum number of nucleoli in diploid and triploid common carp. | |
| CN112691092A (en) | Pharmaceutical composition for treating ischemic heart disease, preparation and application thereof | |
| CN102389439B (en) | Application of Valvate Kiwifruit glycoside E and Valvate Kiwifruit glycoside F in preparation of medicaments for resisting myocardial ischemia | |
| CN102370699A (en) | Application of qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia to preparation of medicament for improving myocardial fibrosis and myocardial hypertrophy | |
| Hurley et al. | Fate map of the eye-antennal imaginal disc in the stalk-eyed fly Cyrtodiopsis dalmanni | |
| Woollard | Recent advances in anatomy | |
| Carter | XVI. A CONTRIBUTION TO THE CYTOLOGY OF THE OVULE OF OROBANCHE MINOR. | |
| Liston et al. | Revisions of the Afrotropical genera of Argidae and species of Pampsilota Konow, 1899 (Hymenoptera, Tenthredinoidea) | |
| Maplestone et al. | Gnathostomiasis in human beings | |
| Kershaw et al. | Observations on Litomosoides Carinii (Travassos, 1919) Chandler, 1931: I.—the Development of the First-Stage Larva: With a Statistical Analysis by | |
| Campbell et al. | The effects of light upon leucocytes and blood-vessels in the mesentery of the living animal | |
| Meirowsky et al. | The response of embryonic chick membrane to Bowen's intraepithelial cancer | |
| Hall et al. | On the locus of action of interstitial cell-stimulating hormone (ICSH or LH) on feather pigmentation of African weaver birds | |
| CN106038797A (en) | Pharmaceutical composition for preventing and treating bladder cancer | |
| Cohn et al. | Studies on the blood vessels in the membranes of chick embryos: part iii. Anatomy and physiology of the blood vessels at different ages | |
| Mahal | Antiseptics and anthelminthics: Part III. Pharmacology of certain flavones with special reference to their anthelminthic action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190312 |